Evidence map›Paper›PMID 39878538›Full record

ReviewFuture medicinal chemistry2025

Transition metal complexes: next-generation photosensitizers for combating Gram-positive bacteria.

Lingmin Pei, Xianyi Yu, Xiaoyu Shan, Guanying Li

Abstract readReview
In one paragraph

Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lingmin PeiSchool of Medicine, Xizang Minzu University, Xianyang, Shaanxi, P. R. China.ORCID 0009-0003-4665-0308
Xianyi YuSchool of Medicine, Xizang Minzu University, Xianyang, Shaanxi, P. R. China.
Xiaoyu ShanSchool of Medicine, Xizang Minzu University, Xianyang, Shaanxi, P. R. China.
Guanying LiDepartment of Biophysics, School of Basic Medical Sciences, Health Science Centre, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R., China.ORCID 0000-0003-4048-2887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise of antibiotic-resistant Gram-positive bacterial infections poses a significant threat to public health, necessitating the exploration of alternative therapeutic strategies. A photosensitizer (PS) can convert energy from absorbed photon into reactive oxygen species (ROS) for damaging bacteria. This photoinactivation action bypassing conventional antibiotic mechanism is less prone to resistance development, making antibacterial photodynamic therapy (aPDT) highly efficient in combating Gram-positive bacteria. Photodynamic transition metal complexes leveraging the unique properties of metals to enhance the aPDT activity are the next-generation PS. This review provides an overview of metal-based PS for combating Gram-positive bacteria. Based on the structures, these metal-PS could be mainly classified as metal-tetrapyrrole derivatives, ruthenium complexes, iridium complexes, and zinc complexes. PS based on complexes of other transition metals such as silver, cobalt, and rhenium are also presented. Finally, we summarize the advantages and shortcomings of these metal- PS, conclude some critical aspects impacting their aPDT performances and give a perspective on their future development.

Indexed as

Anti-Bacterial AgentsCoordination ComplexesGram-Positive BacteriaGram-Positive Bacterial InfectionsPhotosensitizing AgentsTransition ElementsAnimalsHumansPhotochemotherapyAnti-Bacterial AgentsCoordination ComplexesPhotosensitizing AgentsTransition Elementsantibacterial photodynamic therapyGram-positive bacteriaphotosensitizersstructure-activity relationshiptransition metal complexes

Identifiers

PMID39878538
PMCPMC11834427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.